Applying Machine Learning Tools to the ASD Cannabis‑Responsive™ Biomarker Database - Bonni Goldstein

Tags: Autism Spectrum Disorder, Medical Cannabis, Cannabinoids, Autism, Cannabis Medicine, ASD Biomarkers

Bonni Goldstein, MD, presents "Applying Machine Learning Tools to the ASD Cannabis‑Responsive™ Biomarker Database: Paving the way
" at CannMed 24.

Cannabis‑responsive™ (C-Res™) biomarkers are metabolites found in saliva of patients that change in response to medical cannabis (MC) treatment. This objective technology characterizes treatment as successful when C-Res™ values shift to the physiological range determined by typically-developing control groups, and is especially relevant for medical conditions where evaluation of treatment currently relies on subjective evaluation. In a proof-of-concept study, we have demonstrated that the levels of C-Res™ biomarkers found in children with autism spectrum disorder (ASD) shift towards the physiological levels detected in typically developing (TD) children in response to successful physician-directed MC treatment (Siani-Rose et al, 2021 and 2022).

Learn More about CannMed: https://cannmedevents.com/